ArticleBMC infectious diseases2025
Risk factors for poor outcomes in patients with drug-resistant tuberculosis: a 6-year multicenter prospective study in Zhejiang, China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Impact of SARS-CoV-2 infection history on the clinical features and outcomes of patients with recurrent pulmonary tuberculosis: a retrospective case-control study.Annals of medicine · 2026Article
- Risk factors for treatment failure of drug-resistant pulmonary tuberculosis: results from a two-decade data analysis.Journal of thoracic disease · 2026Article
- Tuberculosis notification trends and treatment outcomes in Bangladesh: findings from a National TB Program data, 2019-2021.BMC infectious diseases · 2026Article
- Patterns of Drug Resistance and Treatment Outcomes in Drug-Resistant Tuberculosis Patients in Fuyang City: A Three-Year Retrospective Study.Infection and drug resistance · 2026Article
- Prevalence of comorbidities and their impact on prognosis among patients with rifampicin-resistant tuberculosis: a multicenter retrospective cohort study in China.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAt present, the disease burden of drug-resistant tuberculosis (DR-TB) is still heavy in the world. In this study, we aimed to evaluate the success rate of DR-TB patients after standardized treatment and to analyze the risk factors for poor outcomes in Zhejiang, China.
methodsFrom 2017 to 2021, all culture-confirmed tuberculosis (TB) patients were prospectively enrolled from three designated TB hospitals in Zhejiang, China. Demographic surveys were conducted in all patients, and drug susceptibility of TB strains was tested by fluorescent polymerase chain reaction probe melting curve analysis (MeltPro). DR-TB patients were treated with WHO recommended standardized treatment according to the type of drug resistance, and the outcomes were thoroughly monitored and tracked until June 2023. Binary logistic regression model was used to analyze the related risk factors of poor outcomes in patients with DR-TB. The patients' socio-demographic information, comorbidities, fever, antibiotic use, laboratory test results, lung imaging characteristics and drug resistance characteristics were included in the analysis. A simple TB severity score was developed according to the WHO definition and applied to the analysis.
resultsAmong 1013 patients with confirmed TB, 779 were sensitive to all of the tested drugs (rifampicin, isoniazid, ethambutol, streptomycin and fluoroquinolones), and 234 were resistant to at least one tested drug. Among the 234 DR-TB patients in the study, 50 patients had poor outcomes (23 cases of failure, 13 cases of death, and 14 patients lost to follow-up), 158 patients were successfully treated (125 cases were cured and 33 cases completed treatment), and 26 were referred to other provinces. The overall treatment success rate was 76.0% (158/208). Multivariate analysis showed that age (AOR 1.03; 95%CI 1.01-1.05), previous TB treatment history (AOR 5.03; 95%CI 1.33-18.99), higher TB severity score (AOR 1.48; 95%CI 1.09-2.03), MDR/RR-TB (AOR 8.34; 95%CI 2.99-23.24) and pre-XDR-TB (AOR 9.50; 95%CI 2.24-40.26) were independent risk factors for poor outcomes in DR-TB patients.
conclusionsThe treatment success rate of DR-TB patients in this study reached that of the WHO standard treatment (75%). Physicians should be alert to the possibility of poor outcomes in DR-TB patients with old age, previous TB treatment history, higher TB severity score, MDR/RR-TB or pre-XDR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.